Evidence map›Paper›PMID 38222574›Full record

ArticleACS omega2024

Synthesis, Characterization, Antiglycation Evaluation, Molecular Docking, and ADMET Studies of 4-Thiazolidinone Derivatives.

Ashanul Haque, Mohd Wajid Ali Khan, Khalaf M Alenezi, Raoudha Soury, Muhammad S Khan, Shahzaib Ahamad, Md Mushtaque, Dinesh Gupta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Ashanul HaqueDepartment of Chemistry, College of Science, University of Ha'il, Ha'il 81451, Saudi Arabia.ORCID https://orcid.org/0000-0002-6780-632X
Mohd Wajid Ali KhanDepartment of Chemistry, College of Science, University of Ha'il, Ha'il 81451, Saudi Arabia.
Khalaf M AleneziDepartment of Chemistry, College of Science, University of Ha'il, Ha'il 81451, Saudi Arabia.
Raoudha SouryDepartment of Chemistry, College of Science, University of Ha'il, Ha'il 81451, Saudi Arabia.
Muhammad S KhanDepartment of Chemistry, College of Science, Sultan Qaboos University, Muscat 123, Oman.
Shahzaib AhamadTranslational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg 110067, New Delhi, India.ORCID https://orcid.org/0000-0003-2009-7367
Md MushtaqueDepartment of Chemistry, Millat College (A Constituent College of Lalit Narayan Mithila University), Darbhanga 846003, Bihar, India.
Dinesh GuptaTranslational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg 110067, New Delhi, India.ORCID https://orcid.org/0000-0002-7548-8835
University of Ha'il · SAInternational Centre for Genetic Engineering and Biotechnology · INLalit Narayan Mithila University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The design and development of new small-molecule glycation inhibitors are essential for preventing various chronic diseases, including diabetes mellitus, immunoinflammation, cardiovascular, and neurodegenerative diseases. 4-Thiazolidinone or thiazolidine-4-one is a well-known heterocyclic compound with the potential to inhibit the formation of advanced glycation end products. In the present work, we report the synthesis and characterization of four new 5-arylidene 3-cyclopropyl-2-(phenylimino)thiazolidin-4-one (

Identifiers

PMID38222574
PMCPMC10785283
OpenAlexW4390372853

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.